Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B(CHB). (TDF PEG CHB)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01277601
First received: January 13, 2011
Last updated: March 6, 2014
Last verified: March 2014

January 13, 2011
March 6, 2014
March 2011
July 2015   (final data collection date for primary outcome measure)
HBsAg loss at Week 72 following treatment with 48 weeks of TDF plus PEG combination versus PEG alone for 48 weeks or TDF alone. [ Time Frame: 72 Weeks ] [ Designated as safety issue: No ]
The proportion of subjects with HBsAg loss at Week 72 following treatment with 48 weeks of TDF plus PEG combination versus PEG alone for 48 weeks or TDF alone.
Same as current
Complete list of historical versions of study NCT01277601 on ClinicalTrials.gov Archive Site
  • HBsAg loss at Week 72 following treatment with TDF (48 weeks) plus PEG (16 weeks) combination versus PEG alone for 48 weeks or TDF alone [ Time Frame: 72 Weeks ] [ Designated as safety issue: No ]
    The proportion of subjects with HBsAg loss at Week 72 following treatment with TDF (48 weeks) plus PEG (16 weeks) combination versus PEG alone for 48 weeks or TDF alone.
  • HBsAg loss at Week 96 and Week 120 [ Time Frame: Week 96 and Week 120 ] [ Designated as safety issue: No ]
    The proportion of subjects who experience HBsAg loss at Week 96 and Week 120
  • Rate of quantitative HBsAg decline during the study [ Time Frame: Baseline through Week 120 ] [ Designated as safety issue: No ]
    The rate of quantitative HBsAg decline during the study
  • HBV DNA level < 400 copies/mL at Weeks 72, 96 and 120 [ Time Frame: Weeks 72, 96 and 120 ] [ Designated as safety issue: No ]
    The proportion of subjects with virological response (HBV DNA level < 400 copies/mL) at Weeks 72, 96 and 120
  • HBeAg loss and seroconversion, and HBsAg seroconversion at Weeks 72, 96 and 120 [ Time Frame: Weeks 72, 96 and 120 ] [ Designated as safety issue: No ]
    The proportion of subjects with serological response (HBeAg loss and seroconversion, and HBsAg seroconversion) at Weeks 72, 96 and 120
  • ALT<ULN at Weeks 72, 96 and 120 [ Time Frame: Weeks 72, 96 and 120 ] [ Designated as safety issue: No ]
    The proportion of subjects who experience biochemical response (ALT<ULN) at Weeks 72, 96 and 120
  • Requiring re-initiation or change of therapy while on therapy or post-treatment [ Time Frame: Baseline through Week 120 ] [ Designated as safety issue: Yes ]
    The proportion of subjects who require re-initiation or change of therapy while on therapy or post-treatment
  • Virological response [ Time Frame: Baseline through Week 120 ] [ Designated as safety issue: No ]
    Evaluate virological response (HBV DNA < 400copies/mL)
  • HBsAg loss at Week 72 following treatment with TDF (48 weeks) plus PEG (16 weeks) combination versus PEG alone for 48 weeks or TDF alone [ Time Frame: 72 Weeks ] [ Designated as safety issue: No ]
    The proportion of subjects with HBsAg loss at Week 72 following treatment with TDF (48 weeks) plus PEG (16 weeks) combination versus PEG alone for 48 weeks or TDF alone.
  • HBsAg loss at Week 96 and Week 120 [ Time Frame: Week 96 and Week 120 ] [ Designated as safety issue: No ]
    The proportion of subjects who experience HBsAg loss at Week 96 and Week 120
  • Rate of quantitative HBsAg decline during the study [ Time Frame: Baseline through Week 120 ] [ Designated as safety issue: No ]
    The rate of quantitative HBsAg decline during the study
  • HBV DNA level < 400 copies/mL at Weeks 72, 96 and 120 [ Time Frame: Weeks 72, 96 and 120 ] [ Designated as safety issue: No ]
    The proportion of subjects with virological response (HBV DNA level < 400 copies/mL) at Weeks 72, 96 and 120
  • HBeAg loss and seroconversion, and HBsAg seroconversion at Weeks 72, 96 and 120 [ Time Frame: Weeks 72, 96 and 120 ] [ Designated as safety issue: No ]
    The proportion of subjects with serological response (HBeAg loss and seroconversion, and HBsAg seroconversion) at Weeks 72, 96 and 120
  • ALT<ULN at Weeks 72, 96 and 120 [ Time Frame: Weeks 72, 96 and 120 ] [ Designated as safety issue: No ]
    The proportion of subjects who experience biochemical response (ALT<ULN) at Weeks 72, 96 and 120
  • Requiring re-initiation or change of therapy while on therapy or post-treatment [ Time Frame: Baseline through Week 120 ] [ Designated as safety issue: Yes ]
    The proportion of subjects who require re-initiation or change of therapy while on therapy or post-treatment
Not Provided
Not Provided
 
Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B(CHB).
A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)

The purpose of this study is to evaluate the safety and efficacy of Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon α-2a (PEG) combination therapy versus standard of care TDF monotherapy or PEG monotherapy in non-cirrhotic CHB subjects as determined by loss of HBsAg.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Chronic Hepatitis B
  • Drug: Tenofovir disoproxil fumarate 300 mg(TDF) and Peginterferon α-2a 180 µg(PEG)
    Tenofovir disoproxil fumarate 300 mg(TDF)PO once daily in combination with Peginterferon α-2a 180 µg(PEG) subcutaneous injection once weekly for 48 weeks.
  • Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a
    Tenofovir disoproxil fumarate 300 mg PO once daily in combination with Peginterferon α-2a 180 µg subcutaneous injection once weekly for 16 weeks and Tenofovir disoproxil fumarate 300 mg PO once daily for additional 32 weeks.
  • Drug: Tenofovir Disoproxil Fumarate
    Tenofovir disoproxil fumarate 300 mg PO once daily for 120 weeks.
  • Drug: Peginterferon α-2a
    Peginterferon α-2a 180 µg subcutaneous injection once weekly for 48 weeks.
  • Experimental: Arm A-Treatment Arm 1
    Subjects will be treated with Tenofovir disoproxil fumarate 300 mg(TDF) and Peginterferon α-2a 180 µg(PEG) concomitantly for 48 weeks.
    Interventions:
    • Drug: Tenofovir disoproxil fumarate 300 mg(TDF) and Peginterferon α-2a 180 µg(PEG)
    • Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a
  • Experimental: Arm B- Treatment arm 2
    Subjects will be treated with Tenofovir disoproxil fumarate 300 mg(TDF) and Peginterferon α-2a 180 µg(PEG) concomitantly for 16 weeks followed by Tenofovir disoproxil fumarate 300 mg(TDF)alone for another 32 weeks (total 48 weeks).
    Interventions:
    • Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a
    • Drug: Tenofovir Disoproxil Fumarate
    • Drug: Peginterferon α-2a
  • Active Comparator: Arm C- Active control Arm 1
    Subjects will be treated with Tenofovir disoproxil fumarate 300 mg(TDF) continuously through 120 weeks.
    Intervention: Drug: Tenofovir Disoproxil Fumarate
  • Active Comparator: Arm D- Active control Arm 2
    Subjects will be treated with Peginterferon α-2a 180 µg(PEG) for 48 weeks.
    Intervention: Drug: Peginterferon α-2a
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
751
September 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult subjects (aged 18-75) with CHB (positive for serum HBsAg or HBV DNA for at least 6 months)prior to baseline.
  • Anti-HBV treatment naïve subjects and subjects who have taken oral anti-HBV nucleoside therapy with the last dose ≥ 24 weeks prior to screening are also eligible.
  • Positive or negative for HBeAg
  • HBV DNA ≥ 20,000 IU/ml for HBeAg+ subjects and HBV DNA ≥ 2,000 IU/ml for HBeAg- subjects
  • ALT >54 U/L and ≤ 400 U/L for men and > 36 U/L and ≤ 300 U/L for women
  • Creatinine clearance ≥ 70 mL/min
  • A negative serum pregnancy test is required for female subjects of childbearing potential
  • All sexually active female subjects of childbearing potential must agree to use a protocol recommended method of contraception during heterosexual intercourse throughout the study and for 30 days following the last dose of study medication.
  • Lactating female subjects must agree to discontinue nursing before initiation of study investigational medicinal product.

Exclusion Criteria:

  • Known bridging fibrosis or cirrhosis and/or decompensated liver disease
  • Evidence of hepatocellular carcinoma
  • Significant renal, cardiovascular, pulmonary, neurological, autoimmune disease or bone disease (e.g., osteomalacia,chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis, multiple bone fractures)
  • Absolute neutrophil count < 1,500/mm3, platelet < 100,000/mm3, hemoglobin < 10 g/dL (female) or < 11 g/dL (male)
  • History of severe depression or severe psychiatric disease
  • Thyroid dysfunction
  • Co-infection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)
  • Pregnant
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada,   France,   Germany,   Greece,   Hong Kong,   India,   Italy,   Korea, Republic of,   Netherlands,   Poland,   Portugal,   Romania,   Singapore,   Spain,   Taiwan,   Turkey,   United Kingdom
 
NCT01277601
GS-US-174-0149
No
Gilead Sciences
Gilead Sciences
Not Provided
Not Provided
Gilead Sciences
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP